Cargando…

Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers

Detalles Bibliográficos
Autores principales:	Visram, Alissa, Bredeson, Christopher, Allan, David, Sabloff, Mitchell, Huebsch, Lothar, Tay, Jason, Kekre, Natasha, McDiarmid, Sheryl, Mallick, Ranjeeta, Tinmouth, Alan, Martin, Lisa, Hamelin, Linda, Maze, Dawn
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2018
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5802447/ https://www.ncbi.nlm.nih.gov/pubmed/29379014 http://dx.doi.org/10.1038/s41408-018-0050-2

Ejemplares similares

The Use of Intravenous Antibiotics at the Onset of Neutropenia in Patients Receiving Outpatient-Based Hematopoietic Stem Cell Transplants
por: Hamadah, Aziz, et al.
Publicado: (2012)

Total Body Irradiation without Chemotherapy as Conditioning for an Allogeneic Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia
por: Altouri, Sultan, et al.
Publicado: (2016)

Outcomes of both abbreviated hyper‐CVAD induction followed by autologous hematopoietic cell transplantation and conventional chemotherapy for mantle cell lymphoma: a 10‐year single‐centre experience with literature review
por: Alwasaidi, Turki Abdulaziz, et al.
Publicado: (2015)

Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot study
por: Tay, Jason, et al.
Publicado: (2016)

Plerixafor as a preemptive or salvage therapy for healthy donors with poor mobilization of hematopoietic stem cells
por: Kuang, Pu, et al.
Publicado: (2022)

The Impact of Prolonged Storage of Red Blood Cells on Cancer Survival
por: Kekre, Natasha, et al.
Publicado: (2013)

Plerixafor for autologous CD34(+) cell mobilization
por: Salman, Huda, et al.
Publicado: (2011)

Plerixafor use in autologous hematopoietic stem cell mobilization: Experience from a single center in Southern India
por: Das, Soumya, et al.
Publicado: (2022)

Plerixafor
por: Slater, Susan
Publicado: (2012)

Continuous Multi-Parameter Heart Rate Variability Analysis Heralds Onset of Sepsis in Adults
por: Ahmad, Saif, et al.
Publicado: (2009)

Cyclophosphamide-glucocorticoids versus lenalidomide-dexamethasone as treatment for multiple myeloma at first relapse after autologous stem cell transplantation – a retrospective analysis
por: Sterrett, Russell, et al.
Publicado: (2021)

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update
por: Bilgin, Yavuz M
Publicado: (2021)

Efficacy and safety of plerixafor for hematopoietic stem cell mobilization for autologous transplantation in patients with non-Hodgkin lymphoma and multiple myeloma: A systematic review and meta-analysis
por: Yang, Xiaoyang, et al.
Publicado: (2019)

P1378: PLERIXAFOR AND GRANULOCYTE COLONY STIMULATING FACTOR FOR POOR MOBILIZERS IN PATIENTS UNDERGOING AUTOLOGOUS PERIPHERAL HEMATOPOIETIC STEM CELL TRANSPLANTATION: SINGLE INSTITUTION STUDY
por: El Cheikh, J., et al.
Publicado: (2022)

Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery
por: Green, Michael M. B., et al.
Publicado: (2016)

Use of Plerixafor for Stem Cell Mobilization in the Setting of Autologous and Allogeneic Stem Cell Transplantations: An Update [Corrigendum]
Publicado: (2022)

Hematopoietic Stem Cell Mobilization With Plerixafor Is Safe and Effective in Poorly Mobilizing Acute Myeloid Leukemia Patients
por: Shumilov, Evgenyi, et al.
Publicado: (2019)

Plerixafor combined with standard regimens for hematopoietic stem cell mobilization in pediatric patients with solid tumors eligible for autologous transplants: two-arm phase I/II study (MOZAIC)
por: Morland, Bruce, et al.
Publicado: (2020)

Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Transplantation Seems Less Efficacious in Poor Mobilizers with the Use of a Biosimilar of Filgrastim and Plerixafor: A Retrospective Comparative Analysis
por: Parody, Rocío, et al.
Publicado: (2020)

Successful autologous stem cell collection with filgrastim and plerixafor after long-term lenalidomide therapy for multiple myeloma
por: Agarwal, Rishi, et al.
Publicado: (2012)

Successful “on‐demand” plerixafor for autologous peripheral blood stem‐cells transplantation for relapsed/refractory germ cell tumors
por: Corbingi, Andrea, et al.
Publicado: (2021)

Biased action of the CXCR4-targeting drug plerixafor is essential for its superior hematopoietic stem cell mobilization
por: Jørgensen, Astrid S., et al.
Publicado: (2021)

Modelling Improvements in Cell Yield of Banked Umbilical Cord Blood and the Impact on Availability of Donor Units for Transplantation into Adults
por: Kekre, Natasha, et al.
Publicado: (2013)

The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than Plerixafor
por: Karpova, D, et al.
Publicado: (2013)

Efficacy of Afternoon Plerixafor Administration for Stem Cell Mobilization
por: El Rahi, Cynthia, et al.
Publicado: (2018)

Hematopoietic stem cell mobilization with the reversible CXCR4 receptor inhibitor plerixafor (AMD3100)—Polish compassionate use experience
por: Basak, Grzegorz Wladyslaw, et al.
Publicado: (2010)

Plerixafor enables safe, rapid, efficient mobilization of hematopoietic stem cells in sickle cell disease patients after exchange transfusion
por: Lagresle-Peyrou, Chantal, et al.
Publicado: (2018)

Transfusion of red cells in hematopoietic stem cell transplantation (TRIST): study protocol for a randomized controlled trial
por: Tay, Jason, et al.
Publicado: (2011)

Self-administration of intravenous C1 esterase inhibitor (Berinertâ) in patients with Hereditary Angioedema decreases number of days spent in an emergency room
por: Rizk, Caroline, et al.
Publicado: (2011)

Advocating for the Health Worker
por: McDiarmid, Melissa
Publicado: (2019)

Therapy-related Myelodysplastic Syndrome after Autologous Stem Cell Transplantation Using Plerixafor for Mobilized Stem Cells in a Patient with Multiple Myeloma
por: Tanaka, Hiroaki, et al.
Publicado: (2018)

Safety and Effectiveness of Plerixafor for Peripheral Blood Stem Cell Mobilization in Autologous Stem Cell Transplantation: Results of a Post-Marketing Surveillance Study
por: Tsukada, Nobuhiro, et al.
Publicado: (2021)

The CXCR4 and adhesion molecule expression of CD34+ hematopoietic cells mobilized by “on-demand” addition of plerixafor to granulocyte–colony-stimulating factor
por: Girbl, Tamara, et al.
Publicado: (2014)

Safety and efficacy of plerixafor dose escalation for the mobilization of CD34(+) hematopoietic progenitor cells in patients with sickle cell disease: interim results
por: Boulad, Farid, et al.
Publicado: (2018)

Plerixafor use for peripheral blood stem cell mobilization in Korea
por: Kim, Seok Jin, et al.
Publicado: (2013)

Addition of plerixafor in poorly mobilized allogeneic stem cell donors
por: Zhuang, Lefan, et al.
Publicado: (2022)

From non-preemptive to preemptive scheduling using synchronization synthesis
por: Černý, Pavol, et al.
Publicado: (2016)

Perioperative Comparison of Preemptive and Non-Preemptive Renal Transplant Recipients
por: Aytekin, Sami, et al.
Publicado: (2020)

Hazards of the Health Care Sector: Looking Beyond Infectious Disease
por: McDiarmid, Melissa A.
Publicado: (2014)

Case Study in Refractory Non-Hodgkin's Lymphoma: Successful Treatment with Plerixafor
por: Azim, Hamdy Abdel, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_gi9tdengk4mi3rf4cs683n83pm